Is IDYA a buy according to AI stock analysis?

IDYA AI stock analysis does not call IDEAYA Biosciences an automatic buy. It identifies a clinical-stage precision oncology company with a positive darovasertib registrational readout, about $9.93 of net cash per share, and strong pharma partnerships, but the binary nature of clinical-stage biotech investing means the stock is suitable only for high-risk-tolerant investors who can accept total loss of capital.

What is the IDYA AI stock forecast?

The IDYA AI stock forecast is scenario-based, not a guaranteed target. The current framework uses a bullish range of $55 to $70, a base range of $35 to $48, and a bearish range of $18 to $28, depending on FDA review of darovasertib, clinical trial outcomes, partnership developments, and financing conditions. These are probability-weighted scenarios, not price predictions.

What technical levels matter for IDYA?

The main IDYA technical levels are support near $34 to $35.50, key support near the 200-day moving average at about $32.75 to $33.50, major support near $30 to $31.50, the 52-week low at about $22.09, resistance near $36.50 to $37.10, and the 52-week high at about $40.58. Biotech levels are less reliable than for mature companies because clinical catalysts, not gradual fundamentals, drive most price changes.

Can AI predict IDYA stock price?

No, AI cannot reliably predict stock prices. AI can organize IDEAYA financial data, clinical trial disclosures, partnership terms, cash runway, and analyst targets, but FDA decisions, clinical trial outcomes, competitor developments, and financing events can change the stock price dramatically after the data cutoff.

How should I use this IDYA AI trading strategy?

Use this IDYA AI trading strategy as a research checklist rather than personal advice. Monitor the darovasertib FDA decision timeline, IDE892 Part 2 expansion, IDE849 data, and the August 2026 earnings report; define position size and invalidation rules based on your risk tolerance; track cash burn and share count changes; and decide whether the asymmetric risk profile of a clinical-stage biotech suits your portfolio. IDYA can gap 30-50% in either direction on clinical or regulatory news.

What is the biggest risk in IDYA stock analysis?

The biggest risk in IDYA stock analysis is that an FDA complete response letter or meaningful regulatory delay on darovasertib, or a failed downstream clinical program, could reduce enterprise value sharply. IDEAYA is a pre-profit biotech where most pipeline value depends on binary outcomes. The June 2026 offering of about $345 million gross provides cash runway but also diluted existing holders, and about 10% of shares were sold short at the cutoff.

IDEAYA Biosciences, Inc. research snapshot

IDYA AI Stock Analysis

IDYA AI stock analysis currently reads IDEAYA Biosciences as a clinical-stage precision oncology company whose lead asset, darovasertib, delivered a statistically significant progression-free survival benefit in the registrational OptimUM-02 trial in first-line metastatic uveal melanoma, with an NDA now under expedited FDA review. At the August 3, 2026 data cutoff, the latest available price was about $35.10 and the implied market capitalization was about $3.35 billion using approximately 95.08 million shares. The company ended the reported quarter with $671.2 million in cash and equivalents, and the June 2026 offering added roughly $345 million in gross proceeds, bringing net cash to about $9.93 per share. TTM revenue was $225.27 million (FY2025 $218.71 million) and the TTM net loss was about $140.06 million. This is informational research, not investment advice.

Current price

$35.10

Market cap

About $3.35 billion

AI score

62 / 100

Rating

Clinical-stage precision oncology company with a positive darovasertib registrational readout, a Roche-collaborated MTA-cooperative PRMT5 program (IDE892), and about $9.93 of net cash per share after the June 2026 offering; binary pipeline and regulatory risk still dominates the return profile

Trend status

Uptrend intact above the 200-day moving average after a pullback from the $40.58 July high; darovasertib NDA under expedited FDA review and IDE892 Part 2 monotherapy expansion are the next catalysts

Data cutoff (updated monthly)

August 4, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. IDYA is a publicly traded biotech with SEC filings, quarterly earnings, analyst coverage (15 analysts), partnership disclosures, and clinical trial data. However, forward valuation depends on binary clinical and regulatory outcomes that cannot be reliably forecast from public data alone.
bias Check: The main AI bias risk is over-weighting the darovasertib OptimUM-02 win and the Roche partnership while under-weighting the probability of regulatory setbacks, competitive pipeline displacement (for example Tango Therapeutics in the MTAP-deleted pancreatic space), and the dilutive effect of equity offerings. About 10.07% of shares outstanding were sold short as of the cutoff, signaling an active bear thesis. This review separates disclosed financial, share count, cash, debt, and partnership data from assumptions about approval and commercialization.
ai Confidence: High for share count, cash, debt, revenue, market-cap arithmetic, partnership terms, analyst consensus, and clinical trial status disclosures. Medium for pipeline probability-weighted value because AI cannot predict regulatory decisions or competitor developments. Low for stock price direction beyond scenario ranges.
investment Certainty: Low to medium. IDEAYA has a net cash-rich balance sheet (about $9.93 net cash per share), blue-chip partners, positive registrational data in uveal melanoma, and a plausible platform thesis, but the stock is a pre-profit biotech whose value depends on FDA review, further clinical data, and future financing needs. Binary outcomes dominate the return distribution.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	IDEAYA discovers and develops targeted cancer therapies for patients with specific molecular alterations. The most advanced asset, darovasertib, showed a statistically significant median PFS improvement versus investigator choice in the Phase 2/3 OptimUM-02 trial, while the platform spans synthetic lethality (IDE892, IDE397, IDE161, IDE705, IDE275) and ADC programs (IDE849, IDE034) with partners including Servier, Roche, GSK, and AstraZeneca.	Medium
Moat	The moat comes from a proprietary synthetic lethality discovery platform (DECIPHER, INQUIRE, HARMONY), IP around specific targets, a 1,400-fold selective MTA-PRMT5 cooperative binder in IDE892, and deep pharma relationships. The moat is unproven until drugs reach approval and commercial adoption, and competition in MTAP-deleted and PRMT5 space is intensifying.	Low-medium
Management	CEO and founder Yujiro S. Hata was elected Chairman in June 2026 while remaining President and CEO. The team has built a credible platform, secured blue-chip partnerships, and raised about $345 million gross in June 2026 at $27.00 per share. The key test is executing the darovasertib NDA through FDA review and converting platform science into approved, commercially successful drugs.	Medium
Financial trend	FY2025 revenue was $218.71 million (up about 3,024% from $7.00 million in FY2024) driven by partnership milestones, and TTM revenue was $225.27 million. TTM net loss was about $140.06 million. The company held $671.2 million cash with $28.6 million debt at March 31, 2026, and the June 2026 offering added roughly $345 million gross, raising net cash to about $9.93 per share. Analysts project FY2026 revenue to decline to about $34.08 million as one-time milestones lapse.	High
Valuation	At about $35.10, the local audit calculated roughly 14.85x TTM sales and 3.30x book value, with market cap of $3.35 billion and enterprise value of about $2.4 to $2.9 billion. P/E is not meaningful due to negative earnings. The market is assigning significant pipeline value above net cash.	Medium
Technical trend	IDYA is up about 44.6% over the trailing 52 weeks and trades above both its 50-day ($33.61) and 200-day ($32.78) moving averages after pulling back from the $40.58 July 7 high to about $35.10. RSI near 48 is neutral. Biotech stocks are driven more by clinical catalysts than technical patterns, making levels less reliable than for mature companies.	Low-medium
Risk level	Risk is very high for a pre-profit biotech. Regulatory setback on darovasertib, competitive displacement, equity dilution, cash burn, and binary pipeline outcomes can produce rapid large-magnitude price moves in either direction. About 10.07% of shares were sold short at the cutoff.	High
AI confidence	The evidence base is strong for financial position, share count, analyst consensus, and partnership facts, but AI cannot predict the outcome of FDA review, ongoing clinical trials, or competitive pipeline developments that determine IDYA enterprise value.	Medium for financial data
Investment certainty	IDYA is a high-risk, high-uncertainty biotech investment. A strong net cash position and pharma partnerships provide a floor, but the upside case depends on a successful darovasertib FDA review, further positive clinical data, and commercial execution that may take years to play out.	Low

IDYA AI stock forecast

IDYA AI Stock Forecast Scenarios

The IDYA AI stock forecast uses a pipeline-probability framework rather than a traditional earnings model, since IDEAYA has negative EPS. At the about $35.10 cutoff price, the three scenarios reflect different regulatory, clinical, and financing outcomes over a 3-year horizon. These are model scenarios, not price targets.

Bullish case

$55 to $70

More likely if darovasertib receives FDA approval in uveal melanoma after the expedited review, IDE892 Part 2 monotherapy expansion shows strong efficacy in MTAP-deleted pancreatic and lung cancers, the Roche collaboration on IDE892 plus RG6505 advances and generates milestones, IDE849 (DLL3 ADC) data at ESMO and later readouts are positive, and the company avoids major additional dilution.

Base case

$35 to $48

More likely if darovasertib regulatory review proceeds on a normal timeline with standard questions, IDE892 shows encouraging but early signals, partnership milestones continue at a moderate pace, and the company uses the June 2026 proceeds for R&D without significant new dilution. Analyst consensus averages $53.54 with a median of $50.

Bearish case

$18 to $28

More likely if darovasertib receives a complete response letter or meaningful regulatory delay, IDE892 or IDE397 encounter safety or efficacy issues, a competitor advances a superior mechanism in the same indication, cash burn accelerates without partnership backstop, or further significant dilution is needed to fund operations. Net cash of about $9.93 per share limits the downside relative to a typical pre-revenue biotech.

IDYA AI technical analysis

IDYA AI Technical Analysis

IDYA AI technical analysis uses August 3, 2026 price data from StockAnalysis and Yahoo Finance. Biotech stock technical levels are less reliable than for mature companies because clinical catalyst dates, not gradual fundamentals, drive most price moves. Confirm all levels in a live chart because this page uses a static data cutoff.

Level	Value	Why it matters
Current price	About $35.10	August 3, 2026 close. The intraday price was about $35.20 at 2:38 PM EDT the same day, versus a $35.50 prior close.
Near support	$34 to $35.50	July 2026 consolidation range, with recent lows near $34.01 to $35.27. A hold above this area keeps the post-data uptrend constructive.
Key support	About $32.75 to $33.50	The 200-day moving average sits near $32.78. This zone marks the June-July breakout area and is the first meaningful trend-defining support.
Major support	$30 to $31.50	June 2026 lows near $30.23 to $31.23 that preceded the darovasertib and Roche-driven rally. A sustained break below this area would question the uptrend.
52-week low	About $22.09	The trailing 52-week low. A move toward this level would likely require a significant clinical, regulatory, or financing setback.
Near resistance	$36.50 to $37.10	Late-July highs near $36.50 to $37.06. A close above this range would signal renewed momentum.
Next resistance	$38 to $38.60	July 8 to 9 highs near $38.46 to $38.63. A catalyst-driven move above this would open a test of the 52-week high.
52-week high	About $40.58	The July 7, 2026 intraday high. A breakout above $40.58 on high volume and positive news would be technically significant.
Momentum	Uptrend, neutral near-term	IDYA is up about 44.6% over 52 weeks and trades above the 50-day and 200-day moving averages, but RSI near 48 shows the July pullback neutralized short-term momentum.
Volume	About 0.8 to 1.1 million shares average	StockAnalysis shows roughly 827,000 shares average 20-day volume; Yahoo Finance shows about 1.1 million. Volume spiked to 3.7 to 4.2 million around the June offering and clinical news.
Volatility	Very high for a clinical-stage biotech	IDYA has a beta of about -0.09 (Yahoo), which reflects low correlation with broad market returns. Company-specific clinical and regulatory catalysts drive most individual stock volatility.
Invalidation	Sustained close below $30	A confirmed break below $30 on negative clinical, regulatory, or financing news should trigger a fresh assessment of pipeline probability and cash runway.

IDYA AI trading strategy

IDYA AI Trading Strategy Framework

The IDYA AI trading strategy is a rules-based research framework, not personalized advice. Given the binary nature of biotech catalysts, position sizing and invalidation rules matter more than entry timing. Pair with a live clinical and FDA review calendar, updated cash runway data, and current partnership news.

Catalyst-driven setup

Map the upcoming FDA decision timeline for darovasertib in uveal melanoma, the IDE892 Part 2 monotherapy expansion, IDE849 DLL3 ADC data, and the August 2026 earnings report. Research the expected data quality, competitive landscape, and partnership implications before the event. Do not trade on anticipation alone.

Define a maximum loss before the catalyst. Biotech stocks can gap 30-50% on clinical or regulatory news, so position size must match risk tolerance. Do not average down after a trial or regulatory failure.

Post-selloff recovery setup

If IDYA sells off sharply after a financing, pipeline delay, regulatory question, or mixed data but the core platform thesis remains intact, monitor for stabilization volume and insider buying before considering a position. The about $9.93 net cash per share provides a fundamental floor reference.

Do not buy a falling biotech solely because the cash balance looks attractive. A setback in one program can signal broader platform risk. Wait for clinical or regulatory clarity or insider conviction signals.

Portfolio risk framework

IDYA is a high-conviction-only position that should be sized as a small fraction of a diversified portfolio. Monitor FDA review milestones, share count, partnership milestones, IDE892 expansion enrollment, and cash runway each quarter. Watch the about 10% short interest for crowding risk around binary events.

Reduce or exit if partnership interest wanes, if a competitor shows clearly superior data in the same indication, if insider selling accelerates, if the cash runway shortens without a financing plan, or if the price breaks sustained support below $30.

Investment research summary

Four-master Research Compression

Business essence

IDEAYA discovers cancer drugs for patients with specific genetic changes, using a synthetic lethality platform. Its most advanced asset, darovasertib, targets uveal melanoma and delivered a statistically significant PFS improvement in the registrational OptimUM-02 trial, while the pipeline includes MTA-cooperative PRMT5 (IDE892, collaborated with Roche), MAT2A (IDE397), PARG (IDE161), POLQ (IDE705 with GSK), WRN (IDE275), DLL3 ADC (IDE849, collaborated with AstraZeneca), and KAT6/7 (IDE574). Revenue comes from partnership milestones rather than product sales.

Moat

IDEAYA moat rests on a proprietary synthetic lethality discovery platform (DECIPHER, INQUIRE, HARMONY), a growing IP estate, and deep partnerships with Servier, Roche, GSK, AstraZeneca, Pfizer, Gilead, Novartis, and Jiangsu Hengrui. IDE892 is positioned as a potential best-in-class MTA-cooperative PRMT5 inhibitor with 1,400-fold selective cooperative binding versus SAM-PRMT5. The moat is unproven until drugs pass regulatory review and reach patients, and competitors such as Tango Therapeutics are advancing related mechanisms.

Munger risk inversion

The investment thesis fails if darovasertib receives an FDA complete response letter or meaningful regulatory delay, if IDE892 or IDE397 show insufficient differentiation from competitors, if partnership support weakens, or if the platform fails to generate additional drug candidates. A prolonged cash burn without corresponding value creation would force further dilutive financing. Competitors advancing faster to market with similar mechanisms is another failure path.

Management

CEO Yujiro S. Hata, elected Chairman in June 2026, has led IDEAYA since founding in 2015, building a 145-person organization with blue-chip pharma partnerships. The team has demonstrated capital discipline, pricing a $345 million gross June 2026 offering at $27.00 per share, and scientific credibility with a positive registrational readout. The key test is whether management can convert the darovasertib NDA into FDA approval and commercially successful products.

Industry trend

Precision oncology and synthetic lethality represent a long-duration trend in cancer treatment. Matching drugs to patients with specific genetic alterations is becoming standard of care. IDEAYA operates at the intersection of promising areas: PKC inhibition in uveal melanoma, MTA-cooperative PRMT5 inhibition in MTAP-deleted tumors, MAT2A, WRN helicase inhibition, and DLL3-targeted ADCs. However, the competitive landscape is intensifying as large biopharma and other biotechs pursue the same targets.

Valuation and margin of safety

At about $35.10, IDYA trades at roughly 14.85x TTM revenue and 3.30x book value, with a market cap of about $3.35 billion, enterprise value of about $2.4 to $2.9 billion, and net cash of about $9.93 per share. The market is ascribing significant pipeline value above net cash. Margin of safety is low for a binary-outcome biotech: a regulatory failure could reduce enterprise value sharply, while approval could multiply it.

Source-backed data

IDYA Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
Latest available price	About $35.10 as of August 3, 2026 close; intraday about $35.20; prior close $35.50	StockAnalysis and Yahoo Finance	August 3, 2026
Shares outstanding	Approximately 95.08 million shares, up 4.21% year over year after the June 2026 offering	StockAnalysis statistics	August 3, 2026
Market capitalization audit	$3.35 billion calculated from $35.10 x 95.08M shares, with 0.10% variance against the reported $3.35B	Pineify financial_rigor.py and StockAnalysis	August 3, 2026
TTM revenue and net income	TTM revenue $225.27 million and TTM net loss -$140.06 million, cross-validated between StockAnalysis and Yahoo Finance	StockAnalysis and Yahoo Finance statistics	August 3, 2026
FY2025 financials	Revenue $218.71 million (up about 3,024% from $7.00 million in FY2024), net loss -$113.70 million, EPS -$1.28	StockAnalysis financials	August 3, 2026
Cash, debt, and net cash	$671.2 million cash and equivalents and $28.6 million debt at March 31, 2026, plus the June 2026 offering; net cash about $9.93 per share	StockAnalysis statistics and Yahoo Finance	August 3, 2026
June 2026 offering	7,222,225 shares at $27.00 plus pre-funded warrants for 5,555,576 shares at $26.9999, about $345 million gross, closed June 10, 2026	PR Newswire via Yahoo Finance	August 3, 2026
Valuation ratios	P/S about 14.9x (StockAnalysis) and 13.76x (Yahoo), P/B about 3.3x, EV about $2.4 billion (StockAnalysis) to $2.85 billion (Yahoo). Local audit: P/S 14.85x, P/B 3.30x	StockAnalysis, Yahoo Finance, and Pineify financial_rigor.py	August 3, 2026
Earnings date	Estimated August 5, 2026 before market open (StockAnalysis); Yahoo lists August 10, 2026	StockAnalysis and Yahoo Finance	August 3, 2026
Analyst consensus	Strong Buy from 15 analysts; average 1-year price target $53.54, median $50, range $37 to $66 (StockAnalysis); Yahoo 1-year estimate $52.29	StockAnalysis forecast and Yahoo Finance analysis	August 3, 2026
Recent analyst actions	LifeSci initiated Buy at $62 (Aug 3, 2026); Mizuho reiterated Buy at $50 (Jul 29); Truist maintained Buy, cut target to $63 (Jul 7); RBC maintained Outperform, cut target to $48 (Jul 7); Wedbush reiterated Buy at $58 (Jun 12)	StockAnalysis forecast news feed	August 3, 2026
Darovasertib OptimUM-02 data	Statistically significant and clinically meaningful median PFS improvement versus investigator choice in first-line HLA-A2:01 negative metastatic uveal melanoma, presented at ASCO 2026; NDA submission underway with expedited FDA review	PR Newswire and IDEAYA conference transcripts via StockAnalysis news	August 3, 2026
Short interest	About 9.57 million shares, 10.07% of shares outstanding, roughly 6.71 days to cover	StockAnalysis statistics	August 3, 2026
Financial-rigor verification	Market cap, P/S, P/B, and revenue cross-validation were calculated locally with exact decimal arithmetic	Pineify tools/financial_rigor.py local run	August 3, 2026

Frequently Asked Questions

Read the GSK AI stock analysis Read the AZN AI stock analysis View the CRSP AI stock forecast Open the AI Stock Picker Build an AI trading strategy

This IDYA AI stock analysis page is an informational tool only. It is not investment advice, a solicitation, or a guarantee of returns. Forecast ranges are scenarios based on available public data as of August 3, 2026 and can be wrong if FDA review outcomes, clinical trial results, regulatory decisions, competitive developments, partnership terms, financing needs, equity dilution, cash burn rates, analyst sentiment, or market conditions change.